ArticleCardiovascular diabetology2026
Henagliflozin attenuates adverse ventricular remodeling and improves cardiometabolic parameters in patients with type 2 diabetes and hypertension: real-world evidence from a propensity score-matched analysis.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHenagliflozin has demonstrated favorable glycemic and metabolic effects in phase III trials. However, real-world evidence regarding its impact on cardiac structure-particularly left ventricular mass index (LVMI)-in patients with type 2 diabetes mellitus (T2DM) and concomitant hypertension remains lacking.
methodsIn this single-center, retrospective cohort study, 183 patients with T2DM and hypertension were enrolled. After 1:1 propensity score matching, 132 patients (henagliflozin group, n = 66; control group, n = 66) were included in the primary analysis. The henagliflozin group received henagliflozin 10 mg once daily added to standard-of-care therapy, whereas the control group received standard therapy alone. The primary outcome was the change in LVMI from baseline to 6 months. Secondary outcomes included changes in other echocardiographic parameters (LVEF, E/e', left atrial diameter, LVEDd, IVSd, LVPWT), glycemic indices (FPG, HbA1c), blood pressure, body mass index (BMI), inflammatory markers, and renal function.
resultsAt 6 months, LVMI decreased in the henagliflozin group (from 87.90 ± 18.32 to 85.28 ± 18.20 g/m
conclusionsIn patients with T2DM and hypertension, the addition of henagliflozin to standard therapy over 6 months was associated with significant attenuation of adverse ventricular remodeling-as evidenced by reductions in LVMI, left atrial diameter, and diastolic filling indices-alongside clinically meaningful improvements in glycemic control, blood pressure, and body weight.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.